Andhra HC verdict on Sun Pharma-Ranbaxy merger plea on Saturday

The Andhra Pradesh High Court will tomorrow decide on the petition filed by two investors requesting it to restrain the BSE and NSE from giving any clearance to the scheme of amalgamation or merger between Sun Pharma and Ranbaxy.

After hearing the arguments from the counsels of the petitioners, Ranbaxy, Sun Pharma and SEBI, Justice G Chandraiah said he will pronounce the verdict tomorrow.

The petitioners alleged that there was heavy trading of Ranbaxy stock before the merger with Sun Pharma was announced on April 6, and requested the court to direct the SEBI to investigate the insider trading of Ranbaxy shares and take appropriate action against Sun Pharma and Silver Street Developers.

The court had earlier issued interim orders to maintain status quo with regard to the merger.

During the arguments, Y Suryanarana counsel of SEBI informed the court that an investigation is currently going on into the allegations of insider trading allegations.

Counsel for SEBI also said that the bourses are yet to forward their opinion on the merger or amalgamation issue to the market regulator.

D Prakash Reddy, senior counsel who argued for Ranbaxy said insider trading allegations and merger process are two different issues and hence be dealt with separately and cannot be mixed.

B Adinarayana Rao, counsel for Sun Pharma said the SEBI will investigate allegations of insider trading with regard to the persons involved with that and either Ranbaxy or Sun Pharma as companies have nothing to do with insider trading.

Sun Pharma Counsel also informed the court that merger or amalgamation process involves lengthy processes. The High Courts of Gujarat and Punjab and Haryana will issue public notices when both the companies approach for court approval.

Post new comment

E-mail ID will not be published
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

EDITORIAL OF THE DAY

  • Sebi must not exempt listed SMEs from its mandatory disclosure norms

    The Securities and Exchange Board of India (Sebi) has amended clause 49 of the listing agreement, which lays down the obligation of companies toward t

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

Chander Mohan Sethi

CMD, Reckitt Benckiser India

COLUMNIST

Arun Kumar Jain

Why manufacturing needs innovation

Prime minister Narendra Modi’s call of “come — make in ...

Kuruvilla Pandikattu SJ

Warren Buffett’s key to happiness

Despite being the second richest American, Warren Buffett still lives ...

Gautam Gupta

In fashion, why quality must exceed quantity

Every time there’s a fashion week in India, my friends, ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture